If you've ever walked through a forest after the rain and seen those small, fan-shaped, multicolored shells growing on fallen logs — blue, brown, grey, orange, layered like the plumage of a turkey — then you already know Trametes versicolor. Known as Cola de Pavo in Spanish, Turkey Tail in English, and Kawaratake in Japanese, it is one of the most common fungi on the planet and, paradoxically, one of the most researched in medicine.
PSK and PSP: The Compounds That Changed Japanese Oncology
In the 1970s, the pharmaceutical company Kureha Corporation isolated a polysaccharide from T. versicolor that they named Krestin (PSK). They developed it as an adjunct to chemotherapy and radiotherapy for gastrointestinal cancers. Today, PSK is approved in Japan and widely used in integrative Asian oncology.
PSP (polysaccharide-peptide) is another similar compound, isolated later, with documented immunomodulatory activity.
Both act by selectively stimulating immune-system cells — macrophages, NK cells, T lymphocytes — to support the immune response, and the research underscores that they do so without the adverse effects associated with conventional immunotherapy.
Clinical Evidence in Oncology
A meta-analysis by Eliza et al. (2012, Recent Patents on Inflammation & Allergy Drug Discovery) aggregated 13 clinical trials on Yun Zhi — the Chinese name for Coriolus versicolor, synonymous with Trametes versicolor, i.e., Turkey Tail itself — to evaluate its effect on survival in cancer patients. The authors reported a 9% absolute reduction in 5-year mortality when the preparation was used as an adjunct to conventional treatment, with the most marked benefit in breast, gastric, and colorectal cancers.
Building on this, a Phase I clinical trial (Torkelson, Standish et al., 2012, ISRN Oncology) administered a T. versicolor preparation for six weeks to women with breast cancer who had completed radiotherapy. In this dose-escalation study — small and safety-oriented — an increase in the functional activity of NK cells was observed at a dose of 6 g daily, along with increases in lymphocytes and in CD8+ T and CD19+ B cells. The earlier work of Standish and colleagues (2008) had formulated this immunological hypothesis as its foundation.
The Microbiome: The Most Recent Discovery
A 2014 randomized clinical trial (Pallav et al., Gut Microbes) compared the polysaccharide-peptide (PSP) from T. versicolor against a common antibiotic, amoxicillin, and a control group in 24 healthy adults. The contrast was clear: Turkey Tail's PSP shifted the composition of the gut microbiome in a manner consistent with prebiotic activity, while amoxicillin disrupted it — with a marked increase in Escherichia / Shigella — and that perturbation persisted for weeks after treatment ended.
The polysaccharides in Turkey Tail act as selective prebiotics: indigestible to us, but not to the beneficial bacteria of the colon, which ferment them into short-chain fatty acids (SCFAs) associated with systemic anti-inflammatory effects.
DOI: 10.4161/gmic.29558
Antiviral Activity
The PSP from T. versicolor has shown in vitro inhibitory activity against HIV (human immunodeficiency virus) by interfering with the reverse transcriptase enzyme. These studies are in vitro and do not replace established antiviral treatments, but they open relevant lines of research.
How to Take It
- Powdered extract: 2–3 g daily. Turkey Tail has a mild, slightly earthy flavor.
- As an infusion: Traditionally taken as a tea in Chinese medicine; the powder can also be stirred into broths.
- For general immune support: 1 g daily in cycles of 8–12 weeks.
- As an oncological adjunct: Always under medical supervision and at the doses a professional indicates.
Precautions
- Individuals with organ transplants on immunosuppressants — mandatory consultation with your doctor before use.
- Individuals with autoimmune diseases (lupus, rheumatoid arthritis) — medical supervision required.
- Do not discontinue established oncological treatments. Turkey Tail is a complement, never a substitute.
Educational information. Not a substitute for medical diagnosis or prescription. This product is not intended to diagnose, treat, cure, or prevent any disease (COFEPRIS notice).
References
- Eliza W.L., Fai C.K., Chung L.P. (2012). Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent Patents on Inflammation & Allergy Drug Discovery, 6(1), 78–87. DOI: 10.2174/187221312798889310 · PMID: 22185453
- Pallav K. et al. (2014). Effects of polysaccharopeptide from Trametes versicolor and amoxicillin on the gut microbiome of healthy volunteers: a randomized clinical trial. Gut Microbes, 5(4), 458–467. DOI: 10.4161/gmic.29558 · PMID: 25006989
- Standish L.J. et al. (2008). Trametes versicolor mushroom immune therapy in breast cancer. Journal of the Society for Integrative Oncology, 6(3), 122–128. PMID: 19087769
- Torkelson C.J., Standish L.J. et al. (2012). Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer. ISRN Oncology, 2012, 251632. DOI: 10.5402/2012/251632 · PMID: 22701186